Related Experiment Video
Updated: Sep 13, 2025
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.3K
Preferences between three options for androgen deprivation therapy: a focus group study
Hannah L Rush1,2, Sophie Merrick1, John Marshall3
1MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.
BJU International
|July 31, 2025
Summary
Men want choices for advanced prostate cancer treatment. Many prefer oral LHRH antagonists or transdermal oestradiol patches over traditional LHRH agonist injections for androgen deprivation therapy (ADT).
Area of Science:
- Oncology
- Patient-centered care
- Pharmacology
Background:
- Androgen deprivation therapy (ADT) is a primary treatment for advanced prostate cancer.
- Traditional ADT involves luteinizing hormone-releasing hormone (LHRH) agonist injections.
- Newer ADT options include transdermal oestradiol (tE2) patches and oral LHRH antagonists.
Purpose of the Study:
- To determine if men consider ADT choice important.
- To identify which ADT option men would prefer.
- To explore factors influencing men's ADT choices.
Main Methods:
- Five focus groups were conducted with 24 men in the UK.
- Participants included men with and without prior prostate cancer or ADT.
- Data were analyzed using critical realist thematic analysis.
Main Results:
- Men value having a choice in ADT and involvement in decision-making.
- A majority preferred oral LHRH antagonists (14/24) or tE2 patches (8/24) over LHRH agonist injections (2/24).
- Key influencing factors included side-effects, logistics, and advice from trusted sources.
Conclusions:
- Men desire choices in ADT and often prefer alternatives to LHRH agonist injections.
- These patient preferences should inform guidelines and reimbursement decisions for ADT strategies.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
01:20Disorders of the Male Reproductive System
580
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
580
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
01:21Factors Affecting Drug Response: Overview
2.4K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.4K
01:11Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K